We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Vectivbio Holding Ag
1 own
1 watching
Current Price
$8.48
$0.28
(3.41%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
180.61M
52-Week High
9.29
52-Week Low
2.7426
Average Volume
0M
Dividend Yield
--
P/E Ratio
--
Market Capitalization180.61M
52-Week High9.29
52-Week Low2.7426
Average Volume0M
Dividend Yield--
P/E Ratio--
What does the Vectivbio Holding Ag do?
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Read More
News & Events about Vectivbio Holding Ag.
Globe Newswire
18days ago
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...
Globe Newswire
1month ago
BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held...
Globe Newswire
5 months ago
Combined Gross Proceeds from Public Offering and Private Sale Total $50 MillionBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, ...
Globe Newswire
5 months ago
Interim proof-of-concept data anticipated from STARGAZE in H1 2023 First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease Second clinical indication under evaluation for apraglutide, demonstrating broad potential of this next generation GLP-2 analog ...
Globe Newswire
1 year ago
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)- -IND ...
Frequently Asked Questions
Frequently Asked Questions
What is Vectivbio Holding Ag share price today?
plus_minus_icon
Can Indians buy Vectivbio Holding Ag shares?
plus_minus_icon
How can I buy Vectivbio Holding Ag shares from India?
plus_minus_icon
Can Fractional shares of Vectivbio Holding Ag be purchased?
plus_minus_icon
What are the documents required to start investing in Vectivbio Holding Ag stocks?
plus_minus_icon
What is today’s traded volume of Vectivbio Holding Ag?
plus_minus_icon
What is today’s market capitalisation of Vectivbio Holding Ag?
plus_minus_icon
What is the 52-Week High and Low Range of Vectivbio Holding Ag?
plus_minus_icon
What percentage is Vectivbio Holding Ag down from its 52-Week High?
plus_minus_icon
What percentage is Vectivbio Holding Ag up from its 52-Week Low?
plus_minus_icon
Current Price
$8.48
$0.28
(3.41%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00